ADARx Pharmaceuticals seeks $446 million IPO at $1.74 billion valuation with AbbVie backing

ADARx Pharmaceuticals is pursuing a $446 million IPO at a $1.74 billion valuation, with AbbVie's backing seen as a factor in winning over biotech IPO investors and signaling appetite for RNA therapeutics.

Detected & updated continuously · Source: Nebula